Tocagen Inc (NASDAQ:TOCA) is set to issue its quarterly earnings data after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Tocagen (NASDAQ:TOCA) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. On average, analysts expect Tocagen to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of Tocagen Inc (NASDAQ:TOCA) opened at $10.70 on Tuesday. Tocagen Inc has a 1-year low of $8.60 and a 1-year high of $17.95. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.20 and a current ratio of 7.20.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/tocagen-inc-toca-set-to-announce-quarterly-earnings-on-wednesday/1684907.html.

An institutional investor recently bought a new position in Tocagen stock. California State Teachers Retirement System bought a new stake in shares of Tocagen Inc (NASDAQ:TOCA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,900 shares of the company’s stock, valued at approximately $179,000. California State Teachers Retirement System owned about 0.09% of Tocagen as of its most recent SEC filing. Institutional investors own 37.85% of the company’s stock.

TOCA has been the subject of several recent research reports. Stifel Nicolaus restated a “buy” rating and set a $24.00 price objective on shares of Tocagen in a report on Tuesday, July 25th. Zacks Investment Research downgraded Tocagen from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th.

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.